Clinical Efficacy of Qingke Mixture in Treating Mycoplasma Pneumonia in Children: A Randomized Controlled Trial.

IF 2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of General Medicine Pub Date : 2025-09-03 eCollection Date: 2025-01-01 DOI:10.2147/IJGM.S531095

Xiaofei Xie, Wei Wang, ShengTao Cui, Tianlong Xie, Yongfu Song, Na Wang, Zhuang Wang, Yongji Wang

{"title":"Clinical Efficacy of Qingke Mixture in Treating Mycoplasma Pneumonia in Children: A Randomized Controlled Trial.","authors":"Xiaofei Xie, Wei Wang, ShengTao Cui, Tianlong Xie, Yongfu Song, Na Wang, Zhuang Wang, Yongji Wang","doi":"10.2147/IJGM.S531095","DOIUrl":null,"url":null,"abstract":"Background: Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children, current treatments are limited by resistance and side effects. This study aims to evaluate the clinical efficacy and safety of combining Qingke Mixture with azithromycin for treating MPP in children.Methods: This prospective, randomized, double-blind, controlled trial included 92 children diagnosed with MPP. The treatment group received Qingke Mixture and azithromycin, while the control group received azithromycin alone. Outcomes assessed included clinical symptoms, inflammatory markers, immune response, pulmonary function, and adverse events.Results: The treatment group showed significantly higher clinical efficacy (95.65% vs 80.43%, P < 0.05). The treatment group showed faster resolution of pulmonary symptoms, shorter hospital stays, and greater improvements in pulmonary function and TCM symptom scores (P < 0.05). Inflammatory markers (WBC, CRP, IL-6, IL-8) were significantly lower, while immunoglobulin levels (IgA, IgG, IgM) and T lymphocyte subsets (CD3+, CD4+/CD8+ ratio) were higher in the treatment group compared to the control group (P < 0.05). The incidence of adverse events was low in both groups, with no statistically significant difference.Conclusion: Qingke Mixture combined with azithromycin significantly improves clinical outcomes in children with MPP, enhancing efficacy while maintaining safety.","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"5073-5083"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415112/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S531095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children, current treatments are limited by resistance and side effects. This study aims to evaluate the clinical efficacy and safety of combining Qingke Mixture with azithromycin for treating MPP in children.

Methods: This prospective, randomized, double-blind, controlled trial included 92 children diagnosed with MPP. The treatment group received Qingke Mixture and azithromycin, while the control group received azithromycin alone. Outcomes assessed included clinical symptoms, inflammatory markers, immune response, pulmonary function, and adverse events.

Results: The treatment group showed significantly higher clinical efficacy (95.65% vs 80.43%, P < 0.05). The treatment group showed faster resolution of pulmonary symptoms, shorter hospital stays, and greater improvements in pulmonary function and TCM symptom scores (P < 0.05). Inflammatory markers (WBC, CRP, IL-6, IL-8) were significantly lower, while immunoglobulin levels (IgA, IgG, IgM) and T lymphocyte subsets (CD3+, CD4+/CD8+ ratio) were higher in the treatment group compared to the control group (P < 0.05). The incidence of adverse events was low in both groups, with no statistically significant difference.

Conclusion: Qingke Mixture combined with azithromycin significantly improves clinical outcomes in children with MPP, enhancing efficacy while maintaining safety.

Abstract Image

查看原文本刊更多论文

清咳合剂治疗小儿支原体肺炎的临床疗效：随机对照试验。

背景：肺炎支原体肺炎（Mycoplasma pneumoniae pneumonia， MPP）是儿童常见的呼吸道感染，目前的治疗受耐药性和副作用的限制。本研究旨在评价青可合剂联合阿奇霉素治疗小儿MPP的临床疗效和安全性。方法：这项前瞻性、随机、双盲、对照试验纳入了92名诊断为MPP的儿童。治疗组给予清咳合剂联合阿奇霉素治疗，对照组单独给予阿奇霉素治疗。评估的结果包括临床症状、炎症标志物、免疫反应、肺功能和不良事件。结果：治疗组临床疗效显著高于对照组（95.65% vs 80.43%, P < 0.05）。治疗组肺部症状缓解更快，住院时间更短，肺功能和中医症状评分改善更大（P < 0.05）。治疗组炎症标志物（WBC、CRP、IL-6、IL-8）显著低于对照组，免疫球蛋白水平（IgA、IgG、IgM）和T淋巴细胞亚群（CD3+、CD4+/CD8+比值）显著高于对照组（P < 0.05）。两组不良事件发生率均较低，差异无统计学意义。结论：清咳合剂联合阿奇霉素可显著改善小儿MPP的临床疗效，在保证安全性的同时提高疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of General Medicine Medicine-General Medicine

自引率

0.00%

发文量

1113

审稿时长

16 weeks

期刊介绍： The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.